Ones To Watch News
Refine Search
Pharmaceutical
AstraZeneca’s (Airsupra (albuterol/budesonide) has met the primary endpoint of a Phase III trial, showing a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol. 7 October 2024
Biotechnology
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024
Biotechnology
Kezar Life Sciences has paused its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 7 October 2024
Pharmaceutical
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Biotechnology
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Biotechnology
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Pharmaceutical
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Biotechnology
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
Biotechnology
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Biotechnology
US clinical-stage biotech Spyre Therapeutics says it has appointed of Sheldon Sloan as its chief medical officer (CMO). 3 October 2024
Biotechnology
US biotech Triveni Bio has announced a $115 million Series B to support pipeline expansion. 3 October 2024
Biotechnology
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
Biotechnology
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Pharmaceutical
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Biotechnology
American biotech Shattuck Labs has announced plans to reduce its workforce by approximately 40%, bringing its employee count below 50. 2 October 2024
Pharmaceutical
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Biotechnology
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Pharmaceutical
US biotech Crinetics Pharmaceuticals has released new data on its investigational oral therapy Palsonify (paltusotine), supporting its potential as a convenient alternative to monthly injections for patients with acromegaly. 14 July 2025
Biotechnology
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 11 July 2025
Pharmaceutical
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Biotechnology
BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new chief executive and board director. 11 July 2025
Biotechnology
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
Biotechnology
French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot. 10 July 2025
Biotechnology
China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines, handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform. 10 July 2025
Pharmaceutical
Secarna Pharmaceuticals has formed a strategic collaboration with Vect-Horus aimed at advancing RNA-targeted therapies capable of crossing the blood-brain barrier, a key hurdle in treating central nervous system disorders. 10 July 2025
Biotechnology
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies announced the formalization of an agreement with biologics manufacturing partner, Sweden’s NorthX Biologics, to accelerate the development of Nimivec, Amarna’s next-generation gene therapy platform targeting immune-mediated diseases. 9 July 2025
Pharmaceutical
Shares of US biopharma Rhythm Pharmaceuticals rose 27.4% to $82.96 in early trading today, as it announced positive top-line results from its Phase II trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. 9 July 2025
Pharmaceutical
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 9 July 2025
Biotechnology
Japan’s JCR Pharmaceuticals closed 15% higher after Wednesday’s trading, as it signed a new licensing deal. 9 July 2025
Pharmaceutical
New Jersey, USA-headquartered Champions Oncology, a translational oncology research organization, yesterday announced the full commercial launch of its radiopharmaceutical services platform. 9 July 2025
Pharmaceutical
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
Biotechnology
Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round. 9 July 2025
Biotechnology
US oncology-focused biotech Crescent Biopharma has appointed Jan Pinkas as chief scientific officer (CSO). 8 July 2025
Biotechnology
Debra Barker has been named chief medical officer (CMO) at Centauri Therapeutics, a UK immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications. 8 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze